Updated:
Invoke Capital
Mike Lynch's Invoke Capital blends a family office with a thematic AI venture practice, backing Darktrace and Sophia Genetics from London.
Invoke Capital
Invoke Capital was founded in 2015 as the primary investment vehicle for British entrepreneur Mike Lynch, deploying proceeds from the 2011 sale of enterprise search company Autonomy to Hewlett-Packard. The firm operates from London and functions as a hybrid: a family office for Lynch's personal capital and an opportunistic venture investor in early-stage AI and enterprise software companies spun out of UK research institutions. Lynch's pattern as a founder-investor — he previously incubated and listed Blinkx and ran Autonomy as a public company for over a decade — frames the Invoke proposition. The firm's deployments cluster around applied machine learning and enterprise software, with a preference for businesses that codify scarce human expertise into scalable software products. Stage coverage spans pre-seed through growth, typically leading rounds or structuring direct equity deals rather than fund commitments. Confirmed positions include Darktrace, the Cambridge-born cybersecurity company that uses unsupervised learning to detect network anomalies; Sophia Genetics, a Swiss clinical genomics platform applying AI to patient diagnostics; and Luminance, which applies pattern-recognition algorithms to automate legal document review. The geographic footprint centers on the United Kingdom and Switzerland, with commercial reach extending across Europe and North America. Invoke does not publish team size or asset figures. Its most visible win is Darktrace, which Lynch financially backed and chaired from inception — the company went public on the London Stock Exchange in 2021 at a valuation nearing £1.7 billion. Invoke has periodically organized co-investment syndicates, bringing external institutional capital into rounds alongside Lynch's own balance sheet. No philanthropic foundation bearing the Invoke name is publicly recorded, though Lynch has made personal donations to UK scientific scholarship and policy initiatives. Invoke Capital's structural differentiator is its adjacency to university research ecosystems. Several portfolio companies began as funded projects within Cambridge's computing laboratories, and Lynch's long-standing academic ties give Invoke a sourcing pipeline that most London venture firms cannot replicate. That advantage runs alongside a succession question: Lynch stepped back from a formal executive role after US extradition proceedings began in connection with the HP acquisition dispute, leaving future decision-making authority unclear.
General information
Firm type
Private Equity
Year founded
2015
AUM
Undisclosed (Altss estimate)
Location
Region
Europe
Country
United Kingdom
City
London
Corporate office
London, United Kingdom
Principals
Mike Lynch
Founder
Sector focus
Frequently asked questions
Who runs investment decisions at Invoke Capital?
Founder Mike Lynch has been the central decision-maker since the firm's launch in 2015. Lynch is a Cambridge-trained engineer who founded and led Autonomy, a large enterprise search company, from 1996 through its 2011 sale to HP for $11 billion. He has not publicly designated a formal investment committee or disclosed whether outside partners carry voting authority on Invoke's commitments.
How is Invoke Capital related to Darktrace?
Invoke Capital was the founding investor in Darktrace when the cybersecurity company launched in 2013, with Mike Lynch becoming its chairman. Invoke provided initial seed funding and participated in subsequent rounds before Darktrace listed on the London Stock Exchange in 2021. Lynch and his affiliates maintained a significant equity position through and beyond the IPO.
Is Invoke Capital structured as a family office or a traditional venture firm?
Invoke operates as a hybrid. It primarily deploys Mike Lynch's personal capital from the Autonomy sale, which classifies it as a single-family office. However, it has organized co-investment vehicles that brought institutional investors into select early-stage rounds, giving it some characteristics of a venture capital firm without a formal fund structure.
Which sectors and stages does Invoke Capital target?
Invoke concentrates on applied artificial intelligence and enterprise software companies from pre-seed through growth stages. Its portfolio spans pattern-recognition tools for legal work, clinical genomics diagnostics, and autonomous cybersecurity defense systems. The firm has not publicly disclosed sectors it explicitly avoids.
Where does the underlying wealth come from?
The capital originates from Mike Lynch's proceeds of the 2011 sale of Autonomy to Hewlett-Packard. Lynch received roughly $800 million for his stake, a transaction that later became the subject of extended civil litigation and criminal fraud proceedings in the UK and the United States.
Does Invoke Capital invest in funds or only make direct deals?
Invoke primarily executes direct equity investments rather than committing to external funds. The firm leads seed and early-stage rounds itself and has syndicated follow-on financing alongside institutional co-investors, but no fund-of-funds allocation strategy has been publicly documented.
What is Invoke's known posture on co-investments alongside external GPs?
Invoke has historically welcomed co-investors on a deal-by-deal basis, bringing institutional capital like Talis Capital and institutional VCs into rounds for Darktrace and Luminance. The firm does not market itself as a GP-led syndication platform, nor does it publish co-investment criteria.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on private equity firms?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: